BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28524213)

  • 1. [Update on the treatment of RASopathies].
    Duat-Rodriguez A; Hernandez-Martin A
    Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in RASopathies.
    Aoki Y; Niihori T; Inoue S; Matsubara Y
    J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RASopathies: from pathogenetics to therapeutics.
    Hebron KE; Hernandez ER; Yohe ME
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of craniofacial and dental findings of the RASopathies.
    Cao H; Alrejaye N; Klein OD; Goodwin AF; Oberoi S
    Orthod Craniofac Res; 2017 Jun; 20 Suppl 1(Suppl 1):32-38. PubMed ID: 28643916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy in Noonan syndrome and related disorders.
    Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
    Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
    Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
    Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
    Bezniakow N; Gos M; Obersztyn E
    Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
    Zenker M
    Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
    Hernández-Martín A; Torrelo A
    Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
    Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
    Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New prospectives on treatment opportunities in RASopathies.
    Gelb BD; Yohe ME; Wolf C; Andelfinger G
    Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):541-560. PubMed ID: 36533679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.
    Stevenson DA; Schill L; Schoyer L; Andresen BS; Bakker A; Bayrak-Toydemir P; Burkitt-Wright E; Chatfield K; Elefteriou F; Elgersma Y; Fisher MJ; Franz D; Gelb BD; Goriely A; Gripp KW; Hardan AY; Keppler-Noreuil KM; Kerr B; Korf B; Leoni C; McCormick F; Plotkin SR; Rauen KA; Reilly K; Roberts A; Sandler A; Siegel D; Walsh K; Widemann BC
    Am J Med Genet A; 2016 Aug; 170(8):1959-66. PubMed ID: 27155140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costello syndrome and related disorders.
    Quezada E; Gripp KW
    Curr Opin Pediatr; 2007 Dec; 19(6):636-44. PubMed ID: 18025929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
    Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
    Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
    Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
    Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RASopathies.
    Jafry M; Sidbury R
    Clin Dermatol; 2020; 38(4):455-461. PubMed ID: 32972603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RASopathies: Biology, genetics and therapeutic options.
    Longo JF; Carroll SL
    Adv Cancer Res; 2022; 153():305-341. PubMed ID: 35101235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling RASopathies with Genetically Modified Mouse Models.
    Hernández-Porras I; Guerra C
    Methods Mol Biol; 2017; 1487():379-408. PubMed ID: 27924582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.